Spelling suggestions: "subject:"2-a]pyridine""
1 |
Palladium(II)-Catalyzed Synthesis of 2-(Biphenyl-2-yloxy)pyridines and N-Pyridylcarbazoles via Carbon-Hydrogen Bond ActivationLin, Pi-shan 06 July 2011 (has links)
This thesis is composed of two parts. The palladium-catalysted synthesis of 2-arylphenols and carbazoles via carbon-hydrogen (C-H) bond activation is described. Treatment of 2-phenoxypyridines with two and a half equivalents of potassium aryltrifluoroborate and 10 mol % of Pd(OAc)2 in the presence of two equivalents of Ag2CO3, one equivalent of p-benzoquinone (BQ), and four equivalents of DMSO with (or without) H2O at 130-140 oC for 48 h in dried CH2Cl2 gave the ortho-arylated 2-phenoxypyridines in modest to excellent yields. The investigation of kinetic isotope effect (kH/kD) is determined to be 5.25, which indicates that C-H bond cleavage occurs in the rate-determining step. 2-(Biphenyl-2-yloxy)pyridines was treated with methyl trifluoromethanesulfonate and subsequently sodium methoxide to give the 2-arylphenols to demonstrate the pyridine is a removable directing group. On the other hand, a novel one-pot synthesis for N-pyridylcarbazoles by the reaction of N-phenylpyridin-2-amines with potassium aryltrifluoroborates using Pd(OAc)2 as the catalyst is presented. For instance, reaction of N-phenylpyridin-2-amines with four equivalents of potassium aryltrifluoroborate under the optimal reaction condition gave N-pyridylcarbazoles in 67% yield along with N-(biphenyl-2-yl)pyridin-2-amine in 13% yield. The investigation of kinetic isotope effect (kH/kD) for first C-H bond activation/C-C bond formation step is determined to be 2.14, and that of the second C-H bond activation/C-N bond formation steps is 1.18. On the basis of KIE analysis, it might indicate that first C-H activation undergo direct C-H bond cleacage, and second step should be via electrophilic aromatic substitution.
|
2 |
Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable TargetQuattrini, L., Sadiq, Maria, Petrarolo, G., Maitland, N.J., Frame, F.M., Pors, Klaus, La Motta, C. 10 December 2020 (has links)
Yes / Prostate cancer represents the most common malignancy diagnosed in men, and is the second-leading cause of cancer death in this population. In spite of dedicated efforts, the current therapies are rarely curative, requiring the development of novel approaches based on innovative molecular targets. In this work, we validated aldehyde dehydrogenase 1A1 and 1A3 isoform expressions in different prostatic tissue-derived cell lines (normal, benign and malignant) and patient-derived primary prostate tumor epithelial cells, demonstrating their potential for therapeutic intervention using a small library of aldehyde dehydrogenase inhibitors. Compound 3b, 6-(4-fluorophenyl)-2-phenylimidazo [1,2-a]pyridine exhibited not only antiproliferative activity in the nanomolar range against the P4E6 cell line, derived from localized prostate cancer, and PC3 cell lines, derived from prostate cancer bone metastasis, but also inhibitory efficacy against PC3 colony-forming efficiency. Considering its concomitant reduced activity against normal prostate cells, 3b has the potential as a lead compound to treat prostate cancer by means of a still untapped molecular target.
|
Page generated in 0.0601 seconds